A facelift without the bruising? tranexamic acid put to the test.

NCT ID NCT06345833

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests whether applying tranexamic acid (TXA) directly to the face during facelift surgery can reduce bleeding and bruising better than a placebo. TXA is a medicine that helps blood clots stay intact, and it is already used intravenously for heavy bleeding. Here, it is applied either as an injection mixed with local anesthetic, as a soaked pad held on the skin, or both. Each participant receives TXA on one side of the face and saline on the other, so the comparison is within the same person. The study includes adults who are already scheduled for a facelift and are healthy enough for surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tranexamic acid (TXA) applied topically or locally during facelift surgery
What this could lead to
If effective, topical or local TXA could become a standard way to reduce bleeding and bruising after facelift surgery without the risks of intravenous use.
What could go wrong
This is a very early-phase trial with a small number of participants. It is testing multiple application methods, so it may not identify a clear winner. Although TXA is generally safe, rare allergic reactions or local side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FACELIFT SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Minnesota

    Minneapolis, Minnesota, 55414, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.